In the TC-1 murine model of HPV-driven cancer, both vaccine formulations effectively activated systemic antitumour immune responses, significantly enhancing the infiltration of functional CD8+ T cells and natural killer cells into tumours and promoting the repolarisation of tumour-associated macrophages towards an M1 phenotype. Here, CD8A is linked to cancer.